{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:34:56Z","timestamp":1790357696713,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000262","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000241","name":"Physicians' Services Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.oret.2025.10.019","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:52:41Z","timestamp":1762314761000},"page":"373-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Analysis of Ocular Adverse Events between Aflibercept 8 mg and Faricimab"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4603-826X","authenticated-orcid":false,"given":"Moiz","family":"Lakhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-7033","authenticated-orcid":false,"given":"Abdullah","family":"Al-Ani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Kundapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gholamian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-0027","authenticated-orcid":false,"given":"Emaan","family":"Chaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-6631","authenticated-orcid":false,"given":"Keean","family":"Nanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3929-0482","authenticated-orcid":false,"given":"Nikhil","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2999-6782","authenticated-orcid":false,"given":"Alessandro","family":"Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-8591","authenticated-orcid":false,"given":"Feisal","family":"Adatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim F.","family":"Damji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard R.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.10.019_bib1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2147\/OPTH.S409103","article-title":"Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway","volume":"17","author":"Reitan","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2025.10.019_bib3","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2025.10.019_bib4","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2147\/OPTH.S425709","article-title":"Efficacy, safety, and durability of brolucizumab: an 8-month post-marketing surveillance analysis","volume":"17","author":"Saba","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1017889","article-title":"Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"13","author":"Ma","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oret.2025.10.019_bib6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.10.019_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","article-title":"Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series","volume":"24","author":"Hoffmann","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamaophthalmol.2025.0969","article-title":"Noninfectious intraocular inflammation after intravitreal aflibercept","volume":"143","author":"Binder","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12886-024-03827-6","article-title":"Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report","volume":"25","author":"Hashiya","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","article-title":"Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration","volume":"68","author":"Matsumoto","year":"2024","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib15","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41598-023-27687-0","article-title":"Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.10.019_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ajo.2025.03.023","article-title":"Drugs associated with floppy Iris syndrome: a real-world population-based study","volume":"275","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14740338.2025.2460454","article-title":"Association of ocular adverse events with varenicline solution use: a population-based study","volume":"24","author":"Lakhani","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.oret.2025.10.019_bib20","unstructured":"Lakhani M, Kwan ATH, Chaudry E, et al. A real-world population-based study on the association between cataracts and antipsychotics. Can J Ophthalmol. Forthcoming."},{"key":"10.1016\/j.oret.2025.10.019_bib21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.ophtha.2024.06.011","article-title":"International classification system for ocular complications of anti-VEGF agents in clinical trials","volume":"131","author":"Popovic","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.10.019_bib22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.oret.2025.10.019_bib23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.oret.2025.10.019_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40264-014-0204-5","article-title":"Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank","volume":"37","author":"Caster","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.oret.2025.10.019_bib25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/TCRM.S137144","article-title":"Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs","volume":"13","author":"Arora","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.oret.2025.10.019_bib26","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/bcp.14342","article-title":"Reporting rates of adverse reactions to specialty care medicines exhibit a direct positive correlation with patient exposure: a lack of evidence for the Weber effect","volume":"86","author":"Modgill","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.oret.2025.10.019_bib27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.oret.2025.10.019_bib28","first-page":"84","article-title":"Effects of intravitreal injection on ocular surface and anterior segment parameters","volume":"6","author":"Ulutas","year":"2021","journal-title":"Beyoglu Eye J"},{"key":"10.1016\/j.oret.2025.10.019_bib29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.oret.2025.03.022","article-title":"Endophthalmitis incidence after intravitreal injection of anti-VEGF agents with povidone-iodine versus aqueous chlorhexidine antisepsis","volume":"9","author":"Bates","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.10.019_bib30","article-title":"Effects of povidone-iodine toxicity and aqueous chlorhexidine on ocular surface disease: a brief review","author":"Liu","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.10.019_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/IJO.IJO_1796_23","article-title":"Toxic anterior segment syndrome (TASS): a review and update","volume":"72","author":"Verma","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.oret.2025.03.002","article-title":"Intraocular inflammation after aflibercept prefilled syringe and vial injections","volume":"9","author":"Brown","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.10.019_bib33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12886-019-1284-x","article-title":"Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.10.019_bib35","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00417-013-2266-y","article-title":"Posterior vitreous detachment following intravitreal drug injection","volume":"251","author":"Geck","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib36","first-page":"2393","article-title":"The formation and effect of posterior vitreous detachment during the treatment of diabetic macular edema with bevacizumab","volume":"54","author":"Kasi","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.10.019_bib37","article-title":"Risk of posterior capsular rupture during phacoemulsification in patients with the history of anti-VEGF intravitreal injections: results from the Pan-American Collaborative Retina Study (PACORES) group","volume":"2021","author":"Velez-Montoya","year":"2021","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib38","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1096\/fj.12-225185","article-title":"Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea","volume":"27","author":"Pan","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.oret.2025.10.019_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034210","article-title":"Effect of repeated intravitreal anti-vascular endothelial growth factor drugs on corneal nerves","volume":"102","author":"Qi","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.oret.2025.10.019_bib40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389201023378175","article-title":"Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction","volume":"3","author":"Koren","year":"2002","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.oret.2025.10.019_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2025.10.019_bib42","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ame2.70011","article-title":"The NLRP3 inflammasome pathway contributes to chronic inflammation in experimental autoimmune uveitis","volume":"8","author":"Shome","year":"2025","journal-title":"Animal Model Exp Med"},{"key":"10.1016\/j.oret.2025.10.019_bib43","doi-asserted-by":"crossref","first-page":"9596","DOI":"10.1038\/s41598-019-46116-9","article-title":"Pro-inflammatory role of NLRP3 inflammasome in experimental sterile corneal inflammation","volume":"9","author":"Shimizu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.10.019_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00103-22","article-title":"Essential role of NLRP3 inflammasome in mediating IL-1\u03b2 production and the pathobiology of Staphylococcus aureus endophthalmitis","volume":"90","author":"Kumar","year":"2022","journal-title":"Infect Immun"},{"key":"10.1016\/j.oret.2025.10.019_bib45","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib46","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1167\/iovs.02-1027","article-title":"Human retinal molecular weight exclusion limit and estimate of species variation","volume":"44","author":"Jackson","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.10.019_bib47","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial","volume":"141","author":"Woo","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2024.100742","article-title":"Immunogenicity and potential for intraocular inflammation of intravitreal anti-VEGF drugs","volume":"100","author":"Kim","year":"2024","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.oret.2025.10.019_bib49","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.10.019_bib50","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib51","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1007\/s00417-024-06531-9","article-title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes","volume":"262","author":"Agostini","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib52","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with faricimab","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following intravitreal faricimab","volume":"142","author":"Thangamathesvaran","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib54","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000439008","article-title":"Fusion proteins: aflibercept (VEGF trap-eye)","volume":"55","author":"Sarwar","year":"2016","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.019_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025005032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025005032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:17:50Z","timestamp":1775114270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025005032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2468653025005032"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.10.019","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Analysis of Ocular Adverse Events between Aflibercept 8 mg and Faricimab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}